ID

28335

Descripción

NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Palabras clave

Versiones (2)
  1. 30/11/17 30/11/17 -
  2. 4/1/18 4/1/18 -
Titular de derechos de autor

Prof. Dr. med. Georg Heß

Subido en

4 de enero de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Screening Exclusion criteria GOAL Trial B-cell Lymphoma NCT02499003

Inglés

Screening Exclusion criteria GOAL Trial B-cell Lymphoma NCT02499003

1 formularios  
Admininstrative data
Descripción

Admininstrative data

Alias
UMLS CUI-1
C1320722
Subject ID
Descripción

Subject ID

Tipo de datos

text

Alias
UMLS CUI [1]
C2348585
Exclusion criteria
Descripción

Exclusion criteria

Alias
UMLS CUI-1
C0680251
1. Lymphoma other than DLBCL, FL IIIB, transfomed indolent NHL
Descripción

Lymphoma other

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0024299
UMLS CUI [1,2]
C0205394
2. CNS involvement (brain MRI is required only in cases of clinically suspicious involvement)
Descripción

CNS involvement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0449389
3. Pregnant or breastfeeding women
Descripción

Pregnancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
4. Severe concomitant disease
Descripción

e.g. uncontrolled arterial hypertension, heart failure (NYHA III-IV), uncontrolled diabetes mellitus, pulmonary fibrosis, uncontrolled hyperlipoproteinaemia

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0243087
UMLS CUI [1,2]
C0205082
5. Myocardial infarction within the last 6 months
Descripción

Myocardial infarction

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027051
6. Active uncontrolled infections incl. HIV-positivity, active Hepatitis B or C
Descripción

Hepatitis B Hepatitis C HIV-positive

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019163
UMLS CUI [1,2]
C0019196
UMLS CUI [1,3]
C0019682
7. Vaccination with live vaccine within last 4 weeks
Descripción

Vaccination

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0042196
8. Mental status precluding patient's compliance
Descripción

Mental status compliance

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0278060
UMLS CUI [1,2]
C1321605
9. Known CD20 negativity
Descripción

CD20 negativity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0054946
UMLS CUI [1,2]
C0205160
10. Diagnosed or treated for a malignancy other than NHL
Descripción

Except: adequately treated nonmelanoma skin cancer, curatively treated in-situ cancer of the Cervix, DCIS of the breast, or other solid tumors curatively treated with no evidence of disease for >3 years, or prostate cancer with a life expectancy of more than 2 years

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0006826
11. Treatment with any approved anticancer agent within last 2 weeks
Descripción

Any agents must have been stoppped at least 2 weeks prior to day 1 of GOAL treatment and all treatment-related adverse events must have returned to Grade 1.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0003392
12. Prior exposition to Obinutuzumab or Pixantrone
Descripción

therapy Obinutuzumab Pixantrone

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C2742503
UMLS CUI [1,3]
C0253355
13. History of hypersensitivity to medicinal products with similar chemical structure as the trial medication
Descripción

Hypersensitivity Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
14. Active participation in other interventional clinical trials during the present clinical trial or within the last 2 weeks prior to treatment initiation
Descripción

Concurrent participation in non-treatment studies is not excluded.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
15. Medical or psychological conditions that would jeopardize an adequate and orderly completion of the trial.
Descripción

Compliance behavior Limited (extensiveness) Comorbidity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
Volver a la parte superior de la página

Similar models

Screening Exclusion criteria GOAL Trial B-cell Lymphoma NCT02499003

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Admininstrative data
C1320722 (UMLS CUI-1)
Subject ID
Item
Subject ID
text
C2348585 (UMLS CUI [1])
Item Group
Exclusion criteria
C0680251 (UMLS CUI-1)
Lymphoma other
Item
1. Lymphoma other than DLBCL, FL IIIB, transfomed indolent NHL
boolean
C0024299 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
CNS involvement
Item
2. CNS involvement (brain MRI is required only in cases of clinically suspicious involvement)
boolean
C0449389 (UMLS CUI [1])
Pregnancy
Item
3. Pregnant or breastfeeding women
boolean
C0032961 (UMLS CUI [1])
Severe concomitant disease
Item
4. Severe concomitant disease
boolean
C0243087 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Myocardial infarction
Item
5. Myocardial infarction within the last 6 months
boolean
C0027051 (UMLS CUI [1])
Hepatitis B Hepatitis C HIV-positive
Item
6. Active uncontrolled infections incl. HIV-positivity, active Hepatitis B or C
boolean
C0019163 (UMLS CUI [1,1])
C0019196 (UMLS CUI [1,2])
C0019682 (UMLS CUI [1,3])
Vaccination
Item
7. Vaccination with live vaccine within last 4 weeks
boolean
C0042196 (UMLS CUI [1])
Mental status compliance
Item
8. Mental status precluding patient's compliance
boolean
C0278060 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
CD20 negativity
Item
9. Known CD20 negativity
boolean
C0054946 (UMLS CUI [1,1])
C0205160 (UMLS CUI [1,2])
comorbidity Malignant Neoplasms
Item
10. Diagnosed or treated for a malignancy other than NHL
boolean
C0009488 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
Treatment anticancer agent
Item
11. Treatment with any approved anticancer agent within last 2 weeks
boolean
C0920425 (UMLS CUI [1,1])
C0003392 (UMLS CUI [1,2])
therapy Obinutuzumab Pixantrone
Item
12. Prior exposition to Obinutuzumab or Pixantrone
boolean
C0087111 (UMLS CUI [1,1])
C2742503 (UMLS CUI [1,2])
C0253355 (UMLS CUI [1,3])
Hypersensitivity Investigational New Drugs
Item
13. History of hypersensitivity to medicinal products with similar chemical structure as the trial medication
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
study subject participation status
Item
14. Active participation in other interventional clinical trials during the present clinical trial or within the last 2 weeks prior to treatment initiation
boolean
C2348568 (UMLS CUI [1])
Compliance behavior Limited (extensiveness) Comorbidity
Item
15. Medical or psychological conditions that would jeopardize an adequate and orderly completion of the trial.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial